72 related articles for article (PubMed ID: 7853722)
1. [HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ].
Jingami H
Nihon Rinsho; 1994 Dec; 52(12):3271-8. PubMed ID: 7853722
[TBL] [Abstract][Full Text] [Related]
2. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of hyperlipidemia with HMG-CoA reductase inhibitors].
Prager R
Wien Med Wochenschr Suppl; 1989; 105():17-20. PubMed ID: 2694627
[TBL] [Abstract][Full Text] [Related]
4. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin.
Suárez Y; Fernández C; Gómez-Coronado D; Ferruelo AJ; Dávalos A; Martínez-Botas J; Lasunción MA
Cardiovasc Res; 2004 Nov; 64(2):346-55. PubMed ID: 15485695
[TBL] [Abstract][Full Text] [Related]
5. [Extended worldwide experience. HMG-CoA reductase inhibitors: lovastatin and simvastatin].
Mantell G
Therapie; 1992; 47(2):161-4. PubMed ID: 1412144
[TBL] [Abstract][Full Text] [Related]
6. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.
Tobert JA
Nat Rev Drug Discov; 2003 Jul; 2(7):517-26. PubMed ID: 12815379
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
al Rayyes O; Wallmark A; Florén CH
Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
[TBL] [Abstract][Full Text] [Related]
9. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Branchi A; Rovellini A; Fiorenza AM; Sommariva D
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
[TBL] [Abstract][Full Text] [Related]
10. [Hypercholesterolemia: therapeutic approach].
Alessandri C; Peverini F
Clin Ter; 1991 Jun; 137(6):373-97. PubMed ID: 1832610
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.
Connelly-Smith L; Pattinson J; Grundy M; Shang S; Seedhouse C; Russell N; Pallis M
Exp Hematol; 2007 Dec; 35(12):1793-800. PubMed ID: 17923246
[TBL] [Abstract][Full Text] [Related]
12. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
Schmidt J; Schmitt C; Hockwin O
Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
[TBL] [Abstract][Full Text] [Related]
13. [Maximal therapy of hypercholesterolemia in coronary heart disease].
Thiery J; Armstrong V; Bosch T; Eisenhauer T; Schuff-Werner P; Seidel D
Ther Umsch; 1990 Jun; 47(6):520-9. PubMed ID: 2375008
[TBL] [Abstract][Full Text] [Related]
14. Ocular side effects of the lipid-lowering drug simvastatin? A one year follow-up.
Behrens-Baumann W; Morawietz A; Thiery J; Creutzfeldt C; Seidel D
Lens Eye Toxic Res; 1989; 6(1-2):331-7. PubMed ID: 2488025
[TBL] [Abstract][Full Text] [Related]
15. [HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences].
Geisel J; Oette K; Burrichter H
Fortschr Med; 1990 Feb; 108(4):71-2, 75-6. PubMed ID: 2312032
[TBL] [Abstract][Full Text] [Related]
16. Biochemical aspect of HMG CoA reductase inhibitors.
Endo A; Hasumi K
Adv Enzyme Regul; 1989; 28():53-64. PubMed ID: 2696346
[TBL] [Abstract][Full Text] [Related]
17. Synergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells.
Notarnicola M; Messa C; Refolo MG; Tutino V; Miccolis A; Caruso MG
Lipids Health Dis; 2010 Nov; 9():135. PubMed ID: 21118482
[TBL] [Abstract][Full Text] [Related]
18. [Establishment of a model for evaluating hypolipidemic effect in HepG2 cells].
Niu Y; Lü N; Li Y; Zhao D; Sun C
Wei Sheng Yan Jiu; 2010 Mar; 39(2):155-8. PubMed ID: 20459026
[TBL] [Abstract][Full Text] [Related]
19. Lowering plasma cholesterol by raising ldl receptors. 1981.
Brown MS; Goldstein JL
Atheroscler Suppl; 2004 Oct; 5(3):57-9. PubMed ID: 15531276
[No Abstract] [Full Text] [Related]
20. Lowering plasma cholesterol by raising LDL receptors.
Brown MS; Goldstein JL
N Engl J Med; 1981 Aug; 305(9):515-7. PubMed ID: 6265781
[No Abstract] [Full Text] [Related]
[Next] [New Search]
